Veraxa Biotech AG (VRXA) called an Extraordinary General Meeting for December 10, 2026, at 11:00 AM at Walder Wyss AG in Zurich; doors open at 10:30 AM. The Board of Directors proposes that shareholders elect KPMG AG as statutory auditor for the 2026 business year, after BDO AG announced its resignation as auditor.
Veraxa Biotech AG - Post de-SPAC (VRXA) director Marc Gruninger reported two direct purchases of Ordinary Shares: 9,133 shares at $1.00 per share on October 28, 2026, and 867 shares at $0.98 per share on October 27, 2026. No Rule 10b5-1 plan is reported for these purchases.
Veraxa Biotech AG - Post de-SPAC (VRXA) director Christoph Samuel Ziegler purchased 30,000 ordinary shares on October 20, 2026, at $1.09 per share. His reported direct holdings after the transaction were 37,932 ordinary shares. No Rule 10b5-1 plan is reported.
VRXA (Veraxa Biotech AG) presented first in vivo proof-of-concept and additional in vitro data for its BiTAC-ADC technology at the 17th World ADC Congress. The company reported strong tumor regression in a xenograft breast cancer model after a single systemic dose of 3 mg/kg, with no observed decrease in body weight in the treatment arm.
The release says a construct with one non-targeted component showed no significant effect; a control ADC using the same conjugation and linker-payload technology and drug-antibody ratio performed similarly. Additional in vitro results reported discrimination between cancer and healthy cells, a requirement for both constructs to be co-targeted to the tumor site, and no release of active toxins in the periphery. The company cautions that preclinical results may not predict later-stage trials or results in humans.
Veraxa Biotech AG - Post de-SPAC (VRXA) has a new Section 16 reporting person: Chief Financial Officer Willener Raju Sudir filed an initial statement of beneficial ownership on Form 3. The filing reports no transactions and does not list any reportable holdings or derivative positions at this time.
Veraxa Biotech AG (VRXA) announced the appointment of Raju Willener as Chief Financial Officer, effective September 4, 2026. He will serve as the company’s principal financial and accounting officer and report to CEO and Co-Founder Christoph Antz, Ph.D.
The company highlights that Mr. Willener brings more than three decades of international experience across investment banking, corporate finance, asset management and strategic leadership, including oversight of investment portfolios exceeding CHF 30 billion in assets under management. Veraxa positions this hire as strengthening its capital markets and financial strategy capabilities as it advances its BiTAC-based oncology pipeline. The company also acknowledges the contributions of former CFO Carl von Halem.
Veraxa Biotech AG (VRXA) director Oliver Rolf Baumann reported an indirect open-market purchase of Veraxa ordinary shares. On 2026-08-27, an entity associated with him, Akira Holding AG, purchased 50,000 Ordinary Shares at $1.50 per share. Following this transaction, Akira Holding AG holds 5,773,618 Veraxa ordinary shares that Baumann may be deemed to beneficially own.
Veraxa Biotech AG (VRXA) reported that Chief Executive Officer and director Christoph Rudiger Antz purchased 5,000 Ordinary Shares on 2026-08-27 in a non-derivative, open-market or private transaction at a price of $1.53 per share. Following this transaction, he directly owns 5,000 Ordinary Shares.
Veraxa Biotech Holding AG (VRXA) reported that VERAXA Biotech AG and Secarna Pharmaceuticals achieved an initial research milestone in their antibody oligonucleotide conjugate (AOC) alliance targeting autoimmune and chronic immune diseases. In early in vitro studies, an AOC candidate created using both companies’ technologies showed greater potency than the equivalent unconjugated oligonucleotide, suggesting enhanced therapeutic potential for targeted delivery. Both companies are now discussing the next steps in the collaboration. VERAXA positions this work as an extension of its antibody-based platforms beyond oncology, while Secarna contributes its AI-enabled OligoCreator platform for oligonucleotide discovery and delivery.
Veraxa Biotech Holding AG (VRXA) filed an initial statement of beneficial ownership (Form 3) for reporting person Carl von Halem, who serves as Interim CFO. The filing does not report any equity transactions or holdings, and no Rule 10b5-1 trading plan is indicated.